In this webinar we will be discussing the results of our latest study where we evaluated the ruggedness, repeatability and specificity of commercially available rFC products, as well as our own recombinant product in development, against a large panel of endotoxins.
By Cecilia Avram (Arriello)
By Gillian Ewers (PragmatIC)
By Victoria Rees (European Pharmaceutical Review)
By Phoebe Chubb
By Reeti Banerjee (Fortune Business Insights)